Context Therapeutics Inc (CNTX) Stock Price, Quote & News

Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 225 7416

Website: www.contexttherapeutics.com

Address:

2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States

PaidPiper Feb. 4 at 3:31 AM

$CNTX $ADAPY $NCNA don't forget BURU 🤭

0 · Reply

CATatom Feb. 3 at 10:25 PM

$CNTX I would buy you if it weren't for $ADAPY & $NCNA

0 · Reply

VA_24 Feb. 3 at 3:10 PM

$CNTX

0 · Reply

MedicineMan777 Feb. 3 at 1:00 PM

$CNTX

0 · Reply

LabPsycho Feb. 2 at 8:40 PM

$CNTX @VA_24 I tend to think the A.I. trading bots can't help themselves and tip their hand of what the future holds - while it looked like a suprising recovery from ~ $2.25 to $2.60 today, I suspect it could retrace below the 2.25 again in the next few days. It popped up 100% for some in a very short period of time (days).

1 · Reply

SpencerF Feb. 2 at 5:41 PM

$CNTX any chance of one last pop near $3 before the big boys take it to pennyland again?

0 · Reply

SpencerF Feb. 2 at 4:41 PM

$CNTX just a dip? Or think it was last chance to dump?

1 · Reply

VA_24 Feb. 2 at 3:29 PM

$CNTX Nice dip and recovery

1 · Reply

hugoraciel Feb. 2 at 2:35 PM

$CNTX nice fkn drop

0 · Reply

StockScanners Jan. 31 at 9:27 AM

$CNTX reached 2.85, lets go

1 · Reply

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2025, 7:30 AM EST - 3 months ago

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Nov 5, 2025, 4:15 PM EST - 3 months ago

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Oct 28, 2025, 8:00 AM EDT - 3 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

SKYE

Oct 28, 2025, 7:30 AM EDT - 3 months ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Oct 6, 2025, 7:30 AM EDT - 4 months ago

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Oct 3, 2025, 4:15 PM EDT - 4 months ago

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 6, 2025, 4:11 PM EDT - 6 months ago

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Jun 10, 2025, 7:10 AM EDT - 8 months ago

Context Therapeutics: Undervalued Cancer Fighter

Jun 2, 2025, 7:30 AM EDT - 8 months ago

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

May 29, 2025, 7:30 AM EDT - 8 months ago

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

May 7, 2025, 4:09 PM EDT - 9 months ago

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

May 5, 2025, 4:05 PM EDT - 9 months ago

Context Therapeutics Announces Chief Medical Officer Transition

Apr 30, 2025, 7:30 AM EDT - 9 months ago

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Apr 9, 2025, 7:30 AM EDT - 10 months ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Mar 26, 2025, 4:02 PM EDT - 11 months ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 20, 2025, 4:22 PM EDT - 11 months ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Jan 14, 2025, 4:58 PM EST - 1 year ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Jan 13, 2025, 7:30 AM EST - 1 year ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Nov 6, 2024, 4:06 PM EST - 1 year ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Aug 7, 2024, 4:17 PM EDT - 1 year ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Jul 10, 2024, 2:06 PM EDT - 1 year ago

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

May 8, 2024, 4:06 PM EDT - 1 year ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 2, 2024, 7:31 AM EDT - 1 year ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Apr 1, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Mar 21, 2024, 7:43 AM EDT - 2 years ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Nov 9, 2023, 4:15 PM EST - 2 years ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in Two August 2023 Investor Conferences

May 10, 2023, 4:39 PM EDT - 2 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Apr 18, 2023, 10:15 AM EDT - 3 years ago

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Mar 22, 2023, 5:08 PM EDT - 3 years ago

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Mar 15, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Feb 6, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Jan 31, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Jan 9, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Jan 4, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Dec 8, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Nov 29, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Nov 21, 2022, 9:11 AM EST - 3 years ago

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Nov 9, 2022, 4:14 PM EST - 3 years ago

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in the ThinkEquity Conference

Sep 27, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

PaidPiper Feb. 4 at 3:31 AM

$CNTX $ADAPY $NCNA don't forget BURU 🤭

0 · Reply

CATatom Feb. 3 at 10:25 PM

$CNTX I would buy you if it weren't for $ADAPY & $NCNA

0 · Reply

VA_24 Feb. 3 at 3:10 PM

$CNTX

0 · Reply

MedicineMan777 Feb. 3 at 1:00 PM

$CNTX

0 · Reply

LabPsycho Feb. 2 at 8:40 PM

1 · Reply

SpencerF Feb. 2 at 5:41 PM

$CNTX any chance of one last pop near $3 before the big boys take it to pennyland again?

0 · Reply

SpencerF Feb. 2 at 4:41 PM

$CNTX just a dip? Or think it was last chance to dump?

1 · Reply

VA_24 Feb. 2 at 3:29 PM

$CNTX Nice dip and recovery

1 · Reply

hugoraciel Feb. 2 at 2:35 PM

$CNTX nice fkn drop

0 · Reply

StockScanners Jan. 31 at 9:27 AM

$CNTX reached 2.85, lets go

1 · Reply

MedicineMan777 Jan. 30 at 9:09 PM

$CNTX

0 · Reply

SadyK189 Jan. 30 at 9:09 PM

Here is my Amazing daily "Stocktwits" report : $CNTX $TCGL $LNKS $RPGL CNTX Price 2.19. My post was "Looking good on daily chart. Key support at 1.55 - 1.70. Next key level to test 2.65 - 2.9." It went till 2.84 today TCGL Price 118. My post last night" Massive run today. Still looking good on 4hours chart. Key support at 73 - 81. It can test 181 - 209 zone again." It made a nice move to 355 today LNKS Price 1.15. My post last night" LNKS is trending nicely on daily chart. Key support at 0.87 - 0.91. Next key level to test 1.45 - 1.60." It went till 1.68 today RPGL Price 1.33. My post last night" Looking good on 4hours chart. Key support at 0.88 - 0.96. Next key level to test is 1.65 - 1.80." It went till 2.08 today

0 · Reply

VA_24 Jan. 30 at 9:02 PM

$CNTX Great week bulls Have a blessed weekend Let’s keep the momentum going next week until we get some news

0 · Reply

HIGHTABLETRADES Jan. 30 at 7:30 PM

$CNTX

0 · Reply

HIGHTABLETRADES Jan. 30 at 7:29 PM

$CNTX look at the volume starting January 20th, then repeat after me : VOLUME PRECEDES PRICE 😎

0 · Reply

Nikkosi Jan. 30 at 6:43 PM

$CNTX I watched $RLAY moved from 3’s to $8 in a matter of months. 2026 is our year.

0 · Reply

HIGHTABLETRADES Jan. 30 at 6:32 PM

$CNTX volume baby volume!

0 · Reply

HIGHTABLETRADES Jan. 30 at 6:23 PM

$CNTX laughing now. Scared traders. Scared hands dipping. I hope there are no regrets :)

0 · Reply

HIGHTABLETRADES Jan. 30 at 6:19 PM

$CNTX I’m not being shaken out here.

1 · Reply

KUMO2026 Jan. 30 at 6:17 PM

$CNTX stopped out 2.80

0 · Reply

HIGHTABLETRADES Jan. 30 at 6:10 PM

$CNTX healthy touch of the 30ema. RSI was hot hot

0 · Reply

HIGHTABLETRADES Jan. 30 at 5:53 PM

$CNTX 2.91, 3.41, 4.89, ovarian, endometrial, lung, safe and effective lysis of CLDN6+ cells……lives saved ❤️

1 · Reply

Market Cap	239.80M
Revenue (ttm)	0.00
Net Income (ttm)	-26.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,061,600
Avg Vol	1,516,246
Day's Range	N/A - N/A
Shares Out	91.88M
Stochastic %K	69%
Beta	1.91
Analysts	Strong Sell
Price Target	$5.57